Big Data Is Remaking Big Pharma

Big Pharma is in a rut. The industry keeps spending more and yet making fewer scientific breakthroughs.But help is on the way. GlaxoSmithKline¬†recently¬†announced¬†a radical change in R&D spending. The British drug giant will refocus on data analytics, and the link between the immune system and human disease. It is harbinger of things to come. It … Continue reading Big Data Is Remaking Big Pharma